Barchart.com
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)
0.9200 -0.1400 (-13.21%) 04/14/25 [NASDAQ]
0.9301 x 3,100 0.9746 x 300
Realtime by (Cboe BZX)
0.9301 x 3,100 0.9746 x 300
Realtime 0.9301 +0.0101 (-) 18:11 ET
News & Headlines for Mon, Apr 14th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic Stocktwits - Mon Apr 14, 11:04AM CDT

CEO Bob Valamehr said the RMAT designation recognises the therapy's potential in treating lupus.

VTI : 264.15 (+0.92%)
FATE : 0.9200 (-13.21%)
IWM : 186.53 (+1.18%)
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) GlobeNewswire - Mon Apr 14, 7:00AM CDT

FATE : 0.9200 (-13.21%)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Wed Apr 2, 3:01PM CDT

FATE : 0.9200 (-13.21%)
From Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025 BayStreet.ca - Fri Mar 7, 8:20AM CST

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As cancer rates continue to climb worldwide, the push for innovative treatments has never been more...

ALLO : 1.4300 (-1.38%)
ONCY : 0.5900 (-5.28%)
TARA : 4.14 (+5.88%)
YMAB : 4.93 (+2.07%)
FATE : 0.9200 (-13.21%)
ONC.TO : 0.83 (-5.68%)
Fate Therapeutics: Q4 Earnings Snapshot AP - Wed Mar 5, 3:12PM CST

Fate Therapeutics: Q4 Earnings Snapshot

FATE : 0.9200 (-13.21%)
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates GlobeNewswire - Wed Mar 5, 3:01PM CST

FATE : 0.9200 (-13.21%)
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue Mar 4, 3:01PM CST

FATE : 0.9200 (-13.21%)
Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire - Fri Feb 14, 3:01PM CST

FATE : 0.9200 (-13.21%)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue Feb 4, 3:01PM CST

FATE : 0.9200 (-13.21%)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Jan 3, 3:01PM CST

FATE : 0.9200 (-13.21%)

Barchart Exclusives

Should You Buy Bitcoin Now? This Wall Street Pro Thinks So Barchart - 12 minutes ago
Bitcoin has been consolidating amidst an emerging trade war in recent weeks. BlackRock’s Larry Fink remains bullish as ever on BTC. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
UTC
Reserve Your Spot